Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

Proprotein convertase subtilisin/kexin type 9 (PCSK9) regulates low density lipoprotein receptor (LDLR) protein levels and function. Loss of PCSK9 increases LDLR levels in liver and reduces plasma LDL cholesterol (LDLc), whereas excess PCSK9 activity decreases liver LDLR levels and increases plasma...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Frank-Kamenetsky, Maria, Grefhorst, Aldo, Anderson, Norma N., Racie, Timothy S., Bramlage, Birgit, Akinc, Akin, Butler, David, Charisse, Klaus, Dorkin, Robert, Fan, Yupeng, Gamba-Vitalo, Christina, Hadwiger, Philipp, Jayaraman, Muthusamy, John, Matthias, Jayaprakash, K. Narayanannair, Maier, Martin, Nechev, Lubomir, Rajeev, Kallanthottathil G., Read, Timothy, Röhl, Ingo, Soutschek, Jürgen, Tan, Pamela, Wong, Jamie, Wang, Gang, Zimmermann, Tracy, de Fougerolles, Antonin, Vornlocher, Hans-Peter, Langer, Robert, Anderson, Daniel G., Manoharan, Muthiah, Koteliansky, Victor, Horton, Jay D., Fitzgerald, Kevin
פורמט: Artigo
שפה:Inglês
יצא לאור: National Academy of Sciences 2008
נושאים:
Biological Sciences
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2575310/
https://ncbi.nlm.nih.gov/pubmed/18695239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0805434105
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים